NCT03870425

Brief Summary

The project examines over several days how the distribution pattern of dietary protein stimulate and affect the protein turnover of important proteins in the aging perspective, such as skeletal muscle proteins.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
24

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Apr 2019

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

January 18, 2019

Completed
2 months until next milestone

First Posted

Study publicly available on registry

March 12, 2019

Completed
28 days until next milestone

Study Start

First participant enrolled

April 9, 2019

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2020

Completed
1.7 years until next milestone

Study Completion

Last participant's last visit for all outcomes

February 28, 2022

Completed
Last Updated

November 21, 2022

Status Verified

November 1, 2022

Enrollment Period

1.2 years

First QC Date

January 18, 2019

Last Update Submit

November 18, 2022

Conditions

Keywords

Dietary proteinSarcopeniaProtein turnoverMuscle protein

Outcome Measures

Primary Outcomes (2)

  • Muscle protein synthesis

    Myofibrillar FSR measured by deuterated water technique, by which deuterium labeled alanine incorporation into myofibrillar muscle protein synthesis can be measured.

    3 days

  • Net protein balance

    Whole body net protein balance measured during 10 hours acute study. Measured by the application of stable amino acid labeled phenylalanine and tyrosine tracers, by which the protein synthesis, phenylalanine oxidation and protein breakdown can be calculated.

    10 hours

Secondary Outcomes (8)

  • D5-phenylalanine incorporation

    3 days

  • Muscle protein synthesis

    10 hours

  • Protein synthesis

    10 hours

  • Protein breakdown

    10 hours

  • Phenylalanine oxidation

    10 hours

  • +3 more secondary outcomes

Study Arms (2)

MINCED-SKEWED

PLACEBO COMPARATOR

Minced meat administered with a skewed protein distribution pattern

Other: Distribution pattern of dietary proteins (minced meat)

MINCED-EVEN

EXPERIMENTAL

Minced meat administered with an even protein distribution pattern

Other: Distribution pattern of dietary proteins (minced meat)

Interventions

Study effect of an even or skewed distribution pattern of dietary protein

MINCED-EVENMINCED-SKEWED

Eligibility Criteria

Age65 Years - 80 Years
Sexall
Healthy VolunteersYes
Age GroupsOlder Adult (65+)

You may qualify if:

  • Men and women
  • Between 65-80 years of age

You may not qualify if:

  • BMI above 30
  • Smokers
  • Vegetarians
  • Diabetes or other metabolic diseases
  • Medical treatment which affects protein turnover
  • Gastro-intestinal diseases, reduced kidney or liver function, or chronic inflammation diseases
  • Elevated blood-pressure or signs of atherosclerosis
  • More than 5 hours of regular exercise each week

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Institute of Sports Medicine Copenhagen

Copenhagen, DK-2400, Denmark

Location

Related Publications (1)

  • Agergaard J, Justesen TEH, Jespersen SE, Tagmose Thomsen T, Holm L, van Hall G. Even or skewed dietary protein distribution is reflected in the whole-body protein net-balance in healthy older adults: A randomized controlled trial. Clin Nutr. 2023 Jun;42(6):899-908. doi: 10.1016/j.clnu.2023.04.004. Epub 2023 Apr 8.

MeSH Terms

Conditions

Sarcopenia

Condition Hierarchy (Ancestors)

Muscular AtrophyNeuromuscular ManifestationsNeurologic ManifestationsNervous System DiseasesAtrophyPathological Conditions, AnatomicalPathological Conditions, Signs and SymptomsSigns and Symptoms

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
TRIPLE
Who Masked
CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
PREVENTION
Intervention Model
PARALLEL
Model Details: Randomized controlled
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD, Postdoc

Study Record Dates

First Submitted

January 18, 2019

First Posted

March 12, 2019

Study Start

April 9, 2019

Primary Completion

June 30, 2020

Study Completion

February 28, 2022

Last Updated

November 21, 2022

Record last verified: 2022-11

Data Sharing

IPD Sharing
Will not share

Locations